The Food and Drug Administration (FDA) grants a « Breakthrough Device Designation » to the MIScoli™, an innovative vertebral body tethering device to treat idiopathic scoliosis
The MIScoli system is one of a few VBT devices that are under investigation, or limited market release, in many countries.
MONTREAL, June 18, 2021 /PRNewswire/ - Spinologics Inc. / Spino Modulation Inc., a subsidiary of Spinologics Inc., announced today that the U.S. Food and Drug Administration (FDA) has granted the company a Breakthrough Device Designation for its MIScoli™ system, an innovative vertebral body tethering (VBT) device to treat scoliosis in young adolescents.
The FDA Breakthrough Device Program is intended to help patients receive more timely access to certain medical devices that have the potential to provide more effective treatment for life-threatening or irreversibly debilitating diseases or conditions, including a prioritized review of market approval regulatory submissions.
The MIScoli™ system is one of a few VBT devices that are under investigation, or limited market release, in many countries. Various medical device developers have committed to developing VBT solutions to serve an unmet need in the scoliosis surgical treatment market.
VBT is a promising and lesser invasive alternative to spine fusion, today's standard of care when adolescents need a surgical intervention to correct a curvature of the spine. Patients, and their parents, are looking for treatment options that are less traumatic than fusion, which is associated with long in hospital and at-home recovery times, growth and mobility restrictions, longer term pain and narcotics requirements and significant surgical scars.
Adolescent Idiopathic Scoliosis (AIS) is a common and under diagnosed condition amongst adolescents across the world. It is estimated that 2-3% of the population possess some degree of AIS. If detected, physical rehabilitation and braces are used to delay the progression of spine curvature. In the more severe cases, surgical intervention is needed. Spine fusion is mostly recommended once the patient has finished growing, therefore teenagers must live with a worsening condition until early adulthood. VBT has the potential to disrupt treatment paradigms as it can be performed earlier in the patient's history. A key mechanism to the success of this therapy is by leveraging the patient's growing spine, known as growth modulation.
Spinologics was founded in 2010 by three Orthopedics spine surgeons from Montreal (Canada) to create an environment where they develop surgical tools for back surgery.
Spino-Modulation focuses on the development of the MIScoli™ system, including sponsoring a pivotal clinical trial in Canada.
View original content:SOURCE Spinologics
